All In Biotech

Free tool

FAERS Monitor: Adakveo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761128 or its brand name (Adakveo, Crizanlizumab-Tmca). Reports on generic versions are filed under their own applications.

Reports

1,397

Serious

759

54% of reports

Hospitalization

572

Death reported

55

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • sickle cell anaemia with crisis364
  • pain353
  • back pain151
  • infusion related reaction131
  • arthralgia95
  • pain in extremity89
  • chest pain81
  • nausea80
  • drug ineffective79
  • pyrexia76
  • headache71
  • fatigue68
  • acute chest syndrome52
  • haemoglobin decreased51
  • product dose omission issue44

Reports by year received

View as table
YearReports
20194
2020343
2021426
2022331
2023114
2024113
202545
202621

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,762 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acute chest syndromeSignal52947.6719.645,376
sickle cell anaemia with crisisSignal364355.9325.4125,612
infusion related reactionSignal13129.825.33,623
back painSignal1519.88.41,196
painSignal3538.77.92,453
haemoglobin decreasedSignal517.55.7281
chest painSignal816.65.3381
pain in extremitySignal894.53.7246
arthralgiaSignal953.42.8165
pyrexiaSignal763.32.7122
product dose omission issueSignal442.31.730
headache711.71.421
nausea801.51.214
fatigue681.31.05
drug ineffective790.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.